Agfa-Gevaert Group is consolidating its x-ray film production facilities. The plan involves bringing all related U.S. x-ray film production activity to the company's Bushy Park, SC, facility and closing down
Agfa-Gevaert Group is consolidating its x-ray film production facilities. The plan involves bringing all related U.S. x-ray film production activity to the company's Bushy Park, SC, facility and closing down operations at its Brevard, NC, manufacturing facility by year's end. The action reflects a market shift from medical screen-film to dry hard-copy media and the need to realize worldwide manufacturing efficiencies. It also reflects the company's transition to more environmentally friendly products, according to Robert S. Pryor, president of Agfa HealthCare, Americas. The Brevard facility manufactures aqueous-coated medical x-ray film. North American product demand is shifting from that product to solvent-coated hard-copy media, Pryor said. To keep the Brevard facility in tune with North American customer demands, the company would have to invest in solvent-coating capability, which Pryor described as "financially unattractive." Instead, the company can structure operations in Bushy Park to support North American customers' demand for high-quality diagnostic x-ray film, along with other film and media products. The consolidation is part of a larger, global efficiency initiative that began last year. Facilities in Germany, Belgium, Spain, and the U.K. have also been affected.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.